Sucralfate
- Product NDC
- 62135-106
- Requested package NDC
- 62135-106-44
- 11-digit product format
- 621350106
- Labeler code
- 62135
- Product ID
- 62135-106_5a09df09-04de-a5bd-e063-6294a90a1a7e
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Sucralfate
- Dosage form
- SUSPENSION
- Route
- ORAL
- Labeler
- Chartwell RX, LLC
- Application
- ANDA211780
- Marketing category
- ANDA
- Marketing start
- 2025-04-14
- Substance
- SUCRALFATE
- Active strength
- 1 g/10mL
- Pharmacologic classes
- Aluminum Complex [EPC], Organometallic Compounds [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211780-001 | SUCRALFATE | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211780-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 6a471c1ec25d… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211780-001 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A211780-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A211780-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211780-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A211780-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A211780-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A211780-001 | AB | 1 | 6a471c1ec25d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211780-001 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Sucralfate
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| SUCRALFATE | 1 g/10mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| XX73205DH5 | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 313123 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 37aee721-b9c7-4e6b-a1a1-e826d8541d6b | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sucralfate | SUCRALFATE | Chartwell Governmental & Specialty RX, LLC | d1dfbbf2-ea87-41ce-bcc4-bcba99328ed0 | 2026-09-16 | Warnings, Adverse reactions | 211780 ANDA211780 |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 37aee721-b9c7-4e6b-a1a1-e826d8541d6b | 2026-08-27 | Warnings, Adverse reactions | 211780 ANDA211780 62135-106-44 62135-106 62135010644 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 62135-106-44 | 62135010644 | 420 mL in 1 BOTTLE (62135-106-44) | 420 ml | 2026-08-24 | No | No | Current |